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ABSTRACT
Toxin–antitoxin (TA) modules are small operons in-
volved in bacterial stress response and persistence.
higBA operons form a family of TA modules with
an inverted gene organization and a toxin belonging
to the RelE/ParE superfamily. Here, we present the
crystal structures of chromosomally encoded Vib-
rio cholerae antitoxin (VcHigA2), toxin (VcHigB2) and
their complex, which show significant differences in
structure and mechanisms of function compared to
the higBA module from plasmid Rts1, the defining
member of the family. The VcHigB2 is more closely
related to Escherichia coli RelE both in terms of
overall structure and the organization of its active
site. VcHigB2 is neutralized by VcHigA2, a modu-
lar protein with an N-terminal intrinsically disordered
toxin-neutralizing segment followed by a C-terminal
helix-turn-helix dimerization and DNA binding do-
main. VcHigA2 binds VcHigB2 with picomolar affin-
ity, which is mainly a consequence of entropically
favorable de-solvation of a large hydrophobic bind-
ing interface and enthalpically favorable folding of
the N-terminal domain into an -helix followed by
a -strand. This interaction displaces helix 3 of
VcHigB2 and at the same time induces a one-residue
shift in the register of -strand 3, thereby flipping
the catalytically important Arg64 out of the active
site.
INTRODUCTION
Toxin–antitoxin (TA) modules are small autoregulated
operons found in bacteria and archaea (1,2). They are in-
volved in several physiological functions, most notably in
plasmid stabilization (3), in bacterial stress-response (4,5)
and in the transition to the persister state (6). Most abun-
dant are type II modules, which consist of two genes: one
encoding for a toxin protein and the other for a corre-
sponding antitoxin protein. The toxins shutdown bacterial
metabolismby interferingwith the components of the trans-
lation machinery or with the DNA replication and tran-
scription systems (reviewed in 4,6). In normal growing cells,
the activity of the toxin is controlled by tight binding of the
antitoxin. Activation of the toxins depends on the degra-
dation of the antitoxin by intracellular proteases such as
Lon and is triggered by various stress stimuli, such as nu-
trient deprivation and antibiotic treatment or in the case of
plasmid-residing TA modules plasmid loss (7).
Most prevalent among TA toxins are ribonucleases.
MazF and HicA toxins mostly cleave free mRNA (8,9)
while ribonucleases from the RelE superfamily cleave mR-
NAs in a ribosome-dependent context (10). tRNAs are
also the target of several different types of toxins (11). The
RelE superfamily can be divided into several subfamilies
based on sequence identities of the toxins. Different mem-
bers of the RelE family have historically been given differ-
ent names such as HigB, MqsR, BrnT, YafQ and YoeB, but
the nomenclature does not always coincides well with se-
quence relationships between the toxins. The structures of
different members of the RelE family are known in their
free, ribosome-bound and antitoxin-bound states. Despite
differences in active site residues, all of them bind to the A
site of the translating ribosome (12–14). Some toxins are in-
hibited by the antitoxin that covers the active site (15,16) yet
notable exceptions includeMqsA, PvHigB andYafQ,where
the antitoxin does not interact with the active site (17–20).
The higBA module was first discovered on plasmid Rts1
fromProteus vulgaris (21). It has an unusual, inverted toxin-
before-antitoxin gene organization that was later also ob-
served in some other TA modules such as mqsRA, hicAB
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and brnTA (9,22,23). The crystal structure of the Rts1
plasmid-born higBA from P. vulgaris (from now on referred
to as PvhigBA) shows a toxin with a RelE-type ribonuclease
fold and an unusual antitoxin that is fully structured, with
a single domain harboring both the toxin neutralizing and
DNA binding activities (13,17).
Chromosomal counterparts of the higBA module were
identified on the Vibrio cholerae chromosome II, which
hosts two such modules higBA1 and higBA2. The activa-
tion of these two orthologs depends on the Lon protease
and is triggered by amino acid starvation (24,25). The V.
cholerae HigB2 toxin (VcHigB2) is a ribosome-dependent
RNase that cleaves translating mRNA molecules with a
similar cleavage pattern as Escherichia coli RelE (24,26).
These genes were initially annotated as higBA homologs
given their reverse gene organization. However, sequence
alignments indicate that the active site residues are more
similar to RelE and considering these higBA homologs dis-
play a similar cleavage pattern as RelE, it is assumed they
function as RelE homologs.
In this work, we present the crystal structures of the
VcHigBA2 complex and its components VcHigB2 and
VcHigA2 together with thermodynamics of their mutual
interactions and the structure-activity relationship of the
toxin’s active site. Our results show that there are impor-
tant differences between Vibrio and Proteus encoded higBA
modules concerning the structures of toxin and antitoxin as
well as the neutralization mechanism. The structures of free
and antitoxin-boundVcHigB2 toxin are related by a shift in
the register of a -strand, resulting in two conformations of
the catalytically important Arg64. We discuss this -strand
sliding, which is observed for the first time for a ribonucle-
ase protein, in the context of toxin neutralization.
MATERIALS AND METHODS
Production of VcHigBA2, VcHigB2, VcHigA2 and
VcHigA2N
Peptides (VcHigA23-22 and VcHigA23-33) were obtained
from China Peptides Co., Ltd. and were at least 95% pure
according to the manufacturer. Both peptides contain an
additional tryptophan residue at their C-terminus to en-
able concentration determination by UV spectrophotome-
try. Cloning of the V. cholerae higBA2 operon and purifi-
cation of the VcHigBA2 complex as well as of the individ-
ual VcHigA2 and VcHigB2 proteins have been described
previously (27,28). A sequence corresponding to the trun-
cated version of VcHigA2 containing C-terminal domain
only (residues 37–104) was cloned by a commercial sup-
plier (GenScript) into the pET21b+ vector (Novagen) us-
ing its NdeI and XhoI restriction sites. In this construct
an un-cleavable Histidine tag is placed at the C-terminus of
VcHigA2N and protein was produced following the same
protocol as for the production of VcHigBA2 (27,28).
Selenomethionine-labeled VcHigBA2 complex was pro-
duced using auxotrophic E. coli B834 (DE3) cells. A precul-
ture was grown at 37◦C in SelenoMet medium (Molecu-
larDimensions Limited) supplementedwith ampicillin (100
mg l−1), L-methionine (50 mg l−1) and 0.2% glucose. After
overnight incubation the cells were pelleted, washed with
sterile water and used to inoculate the main culture in the
same medium as before but with L-Se-methionine (50 mg
l−1) added. Cells grown for 10 h at 37◦C (OD600 nm∼1) were
induced with 1 mM IPTG and incubated overnight. From
this point on the complex was purified according to the
same protocol as the unlabeled complex (27).
The concentrations of the proteins and peptides were
determined by measuring UV absorption using extinction
coefficients for proteins calculated according to Pace et
al. (29). The following molar extinction coefficients at 280
nm were used (in M−1 cm−1): 42860 (VcHigBA2 complex,
2:2 stoichiometry), 15930 (VcHigB2), 11000 (full-length
and truncated VcHigA2 dimer), 5500 (VcHigA23-22 and
VcHigA23-33).
Nanobody production
Nanobodies were raised against VcHigB2 via the VIB
Nanobody Service Facility (http://www.vib.be/en/research/
services/Nanobody-Service-Facility). The nanobody gene
sequences were re-cloned into to the pHEN6c expression
vector, which was subsequently transformed into E. coli
WC6 cells. Cell cultures were grown in TB medium sup-
plemented with ampicillin (100 mg l−1) at 37◦C with aer-
ation. The cultures were grown until OD600 nm reached 0.8,
after which the temperature was lowered to 28◦C. Expres-
sion was induced by adding 1 mM IPTG and the cultures
were incubated overnight. Cells were harvested by centrifu-
gation and resuspended in 0.2MTRIS–HCl, 0.5M sucrose,
0.65 mM ethylenediaminetetraacetic acid (EDTA), PH 8.0.
The nanobodies were extracted from the periplasm by os-
motic shock by resuspending cells followed by 45 min incu-
bation at 4◦C with stirring at 200 rpm. The lysate was cen-
trifuged (40 min at 25 000 g) to remove the cell debris and
loaded onto aNi-NTAcolumn equilibrated in 50mMphos-
phate pH 7.0, 1 M NaCl buffer. The column was washed
with five column volumes of 50 mM phosphate pH 6.0, 1
MNaCl buffer to elute the non-specifically bound proteins.
The nanobodies were eluted with 50 mM phosphate pH
4.5, 1 M NaCl. The nanobody-containing fractions were
pooled and neutralized by the addition of 1 M TRIS–HCl
pH 7.4. The pooled fractions were further purified on a Su-
perdex 75 HR 10/30 gel-filtration column run with 20 mM
TRIS-HCl pH 8.0, 150 mMNaCl elution buffer. The purity
of the nanobody samples was analysed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
In vitro activity assay
The activity of VcHigB2 and its neutralization by
VcHigA2 and the VcHigA2-derived peptides was ana-
lyzed by measuring the synthesis of the reporter protein
eGFP using the in vitro synthesis kit (PURExpress,
New England Biolabs). The reactions (12.5 l) were
set up according to the manufacturers’ instructions and
supplemented with 75 ng of purified PCF fragment
(purified using Wizard® SV Gel and PCR Clean-Up
System, Promega) coding for the eGFP reporter protein
(amplified from pPROBE’-GFP plasmid with primers
5′: GCGAATTAATACGACTCACTATAGGGCT–
TAAGTATAAGGAGGAAAAAATATGAGTAAAGG
AGAAGAACTTTTCAC and 3′: AAACCCCTCCGT–
TTAGAGAGGGGTTATGCTAGTTATTATTTTTC
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GAACTGCGGGTGGCTCCATTTGTATAGTTCATC–
CATGCCA. Reactions were incubated for 3 h at 37◦C
in absence and presence of varying amounts of VcHigB2
and its variants, VcHigA2, VcHigA23-22 and VcHigA23-33.
Relative amount of synthesized protein was determined
through fluorescence measurement by diluting the sample
to 60 l and using 483 and 535 nm as excitation and
emission wavelengths. Concentration of WT toxin or toxin
variant required for half-maximal inhibition of reporter
protein synthesis was obtained by fitting the inhibition
curve, which was the average of three experiments, to the
logistic function (Supplementary Figure S4).
In vitro ribosome binding assay
Ribosomes from E. coli MRE600 strain were purified
on 10–50% sucrose gradient in buffer containing 20 mM
HEPES-KOH pH 7.5, 4 mM -mercaptoethanol, 10
mM MgCl2, 150 mM NH4Cl as previously described
(30). Ribosomes were collected top to bottom and the
profiles were measured based on absorption at 280 nm.
Ribosomal fractions were pooled and sucrose was re-
moved using buffer exchange by Amicon 100K filters
(Millipore). We used T7 polymerase to synthesize mRNA
(5′-GGGCAAAACAAAAGGAGGCTAAATATGTTC
TAGCAAAACAAAACAAAA-GAATT-3′) and tRNAs
were extracted from E. coli XL1-Blue cells as previously
described (31). The ribosome binding assays were per-
formed in 10 mM HEPES pH 7.5, 70 mM NH4Cl, 30 mM
KCl, 4 mM MgCl2, 1 mM DTT. Ribosomes were used at
a final concentration of 2 M and were incubated with
2-fold excess of mRNA for 5 min at 37◦C and 4-fold excess
of tRNA for 30 min prior to the assays. VcHigB2 toxin
was added in 5-fold excess and incubated for 20 min. All
the reactions were layered on the sucrose gradient and free
VcHigB2 toxin was also layered on the sucrose gradient
as control. Fractions corresponding to proteins and to
ribosomal fractions were pooled and TCA precipitated,
pellets were washed two times with acetone, air dried and
re-suspended in SDS-loading buffer. Protein and ribosomal
fractions were then analysed by SDS-PAGE and western
blot with antibodies against polyHis tag.
Crystallography
Crystallization and data collection for VcHigBA2,
VcHigA2 and VcHigB2 have been described (27). Com-
plexes of VcHigB2 with nanobodies Nb2, Nb6 and Nb8
were prepared by mixing 1 mg of toxin with 1.3 mg of
nanobody and isolating the pure complex by size-exclusion
chromatography using the BioRad Enrich 70-10-30 col-
umn. Isolated complexes were crystallized using the
hanging drop method. Drops consisting of 1 l of protein
solution (10 mg ml−1 in 200 mMNaCl, 20 mM TRIS–HCl
pH 8.0) and 1 l of precipitant solution were equilibrated
against 110 l precipitant solution. Various commercial
screens were used: Crystal Screen and Crystal Screen
2 (Hampton Research), Morpheus, PACT premier and
ProPlex (Molecular Dimensions) and Jena Classic (Jena
Bioscience). All final crystallization conditions are listed in
Table S1.
All data were measured at the SOLEIL synchrotron (Gif-
sur-Yvette, France) at 100Konbeamline PROXIMA1using
a PILATUS 6M detector. All data were indexed, integrated
and scaled with XDS (32). The structure of the VcHigBA2
complex was determined using SAD phasing. Se-Met sites
were located using SHELXD using the selenium anoma-
lous signal (33) and phases were calculated using PHASER-
EP (34). Following density improvement with PARROT
(35), an initial model was automatically build with BUC-
CANEER (36). The latter was used as a starting point for
iterative refinement with phenix.refine (37) and manual re-
building using Coot (38).
All other structures were solved by molecular replace-
ment using PHASER-MR (34) and using the C-terminal
domain of the VcHigA2 antitoxin or the VcHigB2 toxin as
present in the VcHigBA2 complex as search models. To lo-
cate nanobodies, the co-ordinates of a nanobody against
-lactamase BcII and stripped of its complementarity-
determining region (CDR) loops (39), (PDB ID: 3DWT)
was used as search model. In all cases, the structures were
manually rebuilt usingCoot and refined using phenix.refine.
The final refinement cycles included TLS refinement (one
TLS group per chain). Data collection and refinement
statistics are given in Table S1.
Small angle X-ray scattering
SAXS data were collected at 15◦C in HPLC mode at the
SWING beamline at the SOLEIL synchrotron (Gif-sur-
Yvette, France). The VcHigA2 sample (8 mg/ml in 20 mM
TRIS–HCl pH 8.0 and 200 mM NaCl) was injected into a
Shodex KW 402.5-4F column and ran at 0.2 ml/min. The
data frames (1ms exposure) were interrupted by a dead time
of 0.5 ms. The buffer scatter was measured at the beginning
of the chromatogram (during the dead volume), while the
sample scatter was collected during the peak elution, which
enables the acquisition of data at different protein concen-
trations. The data were processed with Foxtrot (40) and
the ATSAS package (41). After buffer subtraction, Guinier
analysis was performed on each curve using the program
AUTORG (41). The curves of sufficient quality and stable
Rg value along the elution peak were merged into a single
final scatter curve used in further analysis. The molecular
weights of the proteins and the protein complexes was es-
timated by using the QR ratio derived from the invariant
volume of correlation (42).
A model of the VcHigA2 conformational ensemble
was generated using the Ensemble Optimization Method
(EOM) (43). An initial pool of 10 000 random conforma-
tions was generated for the disordered N-terminal segment
(residues 2–37) attached to the folded C-terminal domain
based on the following assumptions: (i) the C distribution
of the disordered segment is one found in random-coils, (ii)
the symmetry of the folded core dimer is C2 (iii) no over-
all structure symmetry is imposed. A final ensemble was se-
lected from the pool of conformations with the EOM algo-
rithm based on the experimental scattering curve and this
process was repeated five times. These final ensembles had
 2 values of 5.9, 1.1, 1.2, 1.2, 1.2 and consisted of 5–7 mod-
els. Based on the RG and DMAX values of the individual
models all ensembles (except the first one) are structurally
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similar. The model ensemble with the lowest  2 value (1.1)
is considered to best represent the true ensemble and struc-
tural parameters of each model in this model ensemble are
given in Supplementary Table S4. The quality of the model
ensemble was assessed using the RSAS and  2FREE param-
eters as proposed recently (42) and is reported in Supple-
mentary Table S3.
CD spectroscopy
Circular dichroism (CD) measurements were carried out
at 25◦C on an Aviv 62A DS CD spectrophotometer (Aviv
Associates, NJ, USA) in a cuvette with 1 mm optical path
length. All data weremeasured in 20mMphosphate pH 7.0,
150 mM NaCl buffer in the wavelength range of 190–250
nm using a spectral bandwidth of 0.5 nm and an averaging
time of 2 s. For measurements of the induction of secondary
structure in the antitoxinVcHigA2 uponVcHigB2 binding,
spectra of freeVcHigB2 (14M), freeVcHigA2 (6M)and
of the VcHigBA2 TA complex (14 M toxin mixed with
6 M antitoxin dimer) were measured. The spectrum of
VcHigA2 in its bound conformation was estimated as dif-
ference spectrum between the spectrum of the VcHigBA2
complex and the spectrum of free VcHigB2 toxin. To esti-
mate the CD spectrum of the antitoxin N-terminal domain
of VcHigA2 in its native unbound state, the spectrum of
the truncated antitoxin variant consisting of the C-terminal
domain only (VcHigA2N) was subtracted from the spec-
trum of the full-length antitoxin (both protein were at 20
M concentration). The CD spectrum of the VcHigA23-33
peptide derived from the VcHigA2 N-terminal domain was
measured at 12 M. The reported mean molar ellipticities
(in degrees cm2 dmol−1) were obtained from the raw data
(ellipticities) by taking into account the molar concentra-
tion (c) and the optical path length (l) through the relation
[θ ] = θ /(c l).
Isothermal titration calorimetry
Samples were dialyzed against 20 mM sodium phosphate
buffer pH 7.5, 150 mM sodium chloride, 1 mM EDTA and
filtered. Prior to the experiments the samples were degassed
for 20 min. All experiments were performed in a VP-ITC
micro-calorimeter (MicroCal, CT, USA). The concentra-
tion of VcHigB2 in the cell was 1 M and the concen-
tration of the macromolecule in the syringe (VcHigA2 or
VcHigA23-22) depended on the desired final stoichiometry.
Raw data were integrated using the MicroCal Origin soft-
ware to obtain the enthalpy change (per mole of ligand
added per injection) as a function toxin/antitoxin ratio r at
temperature T. The enthalpy changes accompanying com-
plex formation were obtained by correcting the measured
enthalpies for the dilution effects (in case of strong binding,
the dilution enthalpy was estimated using the measured en-
thalpy changes above stoichiometric ratios).
Calorimetric curves were measured at four different tem-
peratures (15, 25, 37, 42◦C) that are below the temperatures
that induce unfolding of the protein samples. For the anal-
ysis of the titration curves (enthalpy change H(T,r) mea-
sured at different molar ratios r), a model function was de-
rived based on binding models assuming two equivalent in-
dependent binding sites on theVcHigA2 or one binding site
on the VcHigA2 peptides:
H(T, r ) = [(H◦b (T0) + c◦p(T − T0)
)
∂ν¯/∂r
]
(1)
The derivative ∂ν¯/∂r (ν¯ is the average number of oc-
cupied binding sites), which contains information on the
site binding constant K was derived from the correspond-
ing mass-balance equations and expressed in an analyti-
cal form. The model function is defined at any r and T
by the enthalpy Hb◦(T0) and free energy Gb◦(T0) (
= -RT0·lnK(T0)) of binding (T0 = reference temperature
= 25◦C) and heat capacity of binding c◦p,b (assumed to
be temperature-independent quantity) (30). Values of pa-
rametersHb◦(T0),Gb◦(T0) andc◦p,b were determined
using the global fitting approach based on Levenberg–
Marquardt least-square minimization of the discrepancy
between the model function and experimental titration
curves measured at different T. Validity of the fitted param-
eters was assessed using a Monte-Carlo error propagation
analysis (Supplementary Figure S6).
Structure-based thermodynamic calculations
Polar (AP) and nonpolar (AN) contributions of the solvent
accessible surface were calculated using NACESS 2.1 with
the default set of parameters (44). Change of the solvent
accessible surface due to the formation of the VcHigBA2
was calculated by subtracting total surface of the proteins
in the unbound state from that of the VcHigBA2 complex.
The heat capacity change was estimated by the relation in-
troduced by Murphy and Freire (45).
RESULTS
Crystal structure of VcHigB2
As VcHigB2 resisted crystallization by conventional meth-
ods we used VcHigB2-specific cameloid single-chain an-
tibody fragments as crystallization chaperones. From the
blood of a single llama immunized with VcHigB2, a library
was constructed that was panned for VcHigB2 binders us-
ing phage display. From this library, 10 unique nanobody
sequences were obtained, of which fivewere used to produce
protein (selection was based on good expression yields).
From these five nanobodies, three (Nb2, Nb6 and Nb8)
eventually gave crystals of sufficient quality for structure
determination. In these three complexes nanobodies are
bound to different VcHigB2 epitopes and the resulting
structures of the VcHigB2 are very similar––with 0.7 A˚
(VcHigB2-Nb6 versus Nb8) and 1.4 A˚ (VcHigB2 Nb2 ver-
sus Nb6) rmsd for 94 out of 110 C atoms (Supplemen-
tary Figure S1). This suggest that nanobody binding does
not significantly disturb the fold of the protein, and that the
conformation ofVcHigB2 observed in these crystals may be
a good approximation to that of the toxin in the unbound
state.
The VcHigB2 toxin consists of a four-stranded antipar-
allel -sheet core flanked by two N-terminal -helices (he-
lices 1 and 2) on one side and a longer C-terminal -helix
(helix 3) on the other side (Figure 1A). This architecture
is typical for a large family of microbial RNases that in-
cludes other TA related mRNA interferases such as RelE,
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Figure 1. The structure and activity ofVcHigB2 toxin. (A) Left: the struc-
ture of the VcHigB2 toxin. Secondary structure elements and positively
charged 2-3 loop, which is missing from the model are indicated. Ac-
tive site residues are shown as blue sticks. Right: detailed view of the ac-
tive site residues, which coordinate two sulphate ions from the crystalliza-
tion mixture (yellow). The mRNA (gray) as found in the EcRelE-ribosome
structure (PDB ID: 4V7J) is superimposed for comparison. The side chain
of Lys84 lacks clear electron density, but is modeled here in a likely po-
sition and shown as dashed stick. (B) Comparison of the active site of
the VcHigB2 (red) and the EcRelE (green, PDB ID: 3KHA). VcHigB2
residues (blue sticks) that correspond to the active site residues of EcRelE
(green sticks) are shown. (C) Concentrations of WT toxin and its variants
to achieve half-maximal inhibition of the reporter protein synthesis in the
in vitro activity assay.
MqsR, YoeB and YafQ (15,18–20,46). Electron density is
seen for the entire molecule except for the affinity tag and
residues Ala53-Ser63 of loop 2-3, which has a disorder-
promoting sequence ASKGKGRGGS (dashed line in Fig-
ure 1A).
A DALI search identified E. coli RelE (EcRelE, PDB
3KHA, DALI score 9.6, (47)) as the closest structural rel-
ative of VcHigB2. Although VcHigB2 and EcRelE share
only 17% sequence identity, their tertiary structures are well
preserved (2.5 A˚ rmsd for 82 of 94 C atoms). Notable dif-
ferences are observed for the packing of the C-terminal he-
lix against the -sheet core and for loop 2-3, which is
structured and significantly shorter in EcRelE (Figure 1B).
Apart from EcRelE, VcHigB2 shares high structural simi-
larity with RelJ, YoeB, YafQ, the archeal RelEs (which are
all ribonucleases,(15,19,46) and also with Caulobacter cres-
centus ParE and E. coli O157 ParE2 (48,49), which have
different biochemical activities (Supplementary Figure S2,
sequence identities and DALI scores are given in Supple-
mentary Table S2). Surprisingly, plasmid-born PvHigB, to-
gether with BrnT from Brucella abortus and MqsR from E.
coli belongs to the more distant relatives (Supplementary
Figure S2 and Table S2, (17,18)). While the -sheet core is
still preserved, these toxins completely lack the C-terminal
helix 3 and also differ in the arrangement and number of
N-terminal helices.
VcHigB2 has a RelE-like active site
Similar to EcRelE (24,26), the ribosome bound VcHigB2
toxin cleaves translating mRNA molecules after the sec-
ond codon position without a strong sequence preference.
The active site of VcHigB2 is located on the -sheet surface
and is almost identical to the active site of EcRelE (Figure
1B). The active site surface is positively charged, suggesting
strong electrostatic interactions with the negatively charged
mRNA phosphate backbone. Two sulphate ions are located
in the active site of VcHigB2, strongly resembling the posi-
tions of backbone phosphates of themRNAmolecule in the
RelE-ribosome structure (Figure 1A, (12)). It is not uncom-
mon for ribonucleases to harbor a sulphate or phosphate
ion in their active site cleft in absence of a substrate, and
has been observed for other RelE family members such as
YafQ (20).
Based on the sequence alignment and structural simi-
larity with EcRelE (sequence alignment is shown in Sup-
plementary Figure S3) we prepared several variants of
VcHigB2 with alanine substitutions of the presumed active
site residues (Arg51, Arg64, Tyr82 and Lys84). For all of
these toxin variants orders of magnitude higher concentra-
tions are needed to inhibit synthesis of a reporter protein
in our in vitro translation assay compared to the WT toxin
(Figure 1C and Supplementary Figure S4). Most disruptive
is the substitution of Lys84 leading to a 3000-fold drop in
toxin activity, followed by Tyr82 with a 1200-fold reduction
(Figure 1C). Substitutions of Arg51 and Arg64 on strands
2 and 3, which coordinate a sulphate ion in our structure,
were less disruptive (170- and 350-fold reduction relative to
WT). Similar to EcRelE, the active site of VcHigB2 toxin
lacks a His-Glu or His-His acid-base pair as is commonly
found in RNases and other members of the RelE super-
family. Recent data on the cleavage mechanism of EcRelE
points toward a model where the acid-base pair consists of
an arginine (Arg81) and a lysine (Lys54) residue (50,51). In-
terestingly, inVcHigB2 this arginine is structurally replaced
by Lys84 while the lysine is replaced by Arg51. We also
tested a toxin variant where the positively charged flexible
2-3 loop (residues 54–63) is substituted by a sequence
of three alanines. This modification reduces the activity by
120-fold relative to the WT enzyme (Figure 1C).
VcHigA2 contains of a helix-turn-helix DNA
binding/dimerization motif
TheVcHigA2 antitoxin counteracts theVcHigB2 toxin and
rescues growth-stalled bacterial cells (24). The molecular
weight estimate for VcHigA2 from SAXS is in accordance
with previous estimates from analytical gel-filtration exper-
iments, which indicates that this antitoxin is a dimer (Sup-
plementary Table S3, (28)). Crystals of the C-terminal do-
main of VcHigA2 (residues 38–104) were obtained after a
4-month waiting period from trials utilizing the full length
protein (27). These crystals contain in their asymmetric unit
four dimers of the C-terminal domain arranged around
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a non-crystallographic four-fold axis while the N-terminal
domain is absent due to degradation as shown before (27).
TheVcHigA2C-terminal domain is a Lambda repressor-
like DNA binding domain. The domain has a small hy-
drophobic core surrounded by five -helices (Figure 2A).
The dimerization interface is formed by helices 4 and 5,
while helices 2 and 3 form a characteristic HTH motif
that likely binds the operator DNA. This arrangement dif-
fers dramatically from the PvHigA where the dimerization
interface is formed by a longer helix 5. This results in an
overall distinct relative orientation of the two monomers in
the dimer, and thus a different relative disposition of the
two DNA binding motifs (Supplementary Figure S5, (17)).
Taken together the DNA-binding domain of the VcHigA is
more similar to theMqsA antitoxin (PDB ID: 3GN5, (18)),
while that ofPvHigA antitoxin seems to belong to a distinct
group ofHTHproteins that also includesHigA fromE.Coli
(PDB 2ICT) and Coxiella brunetii (PDB ID: 3TRB).
The N-terminal region ofVcHigA2 is intrinsically disordered
Several lines of evidence suggest that the VcHigA2 N-
terminal region (residues 1–36), which was not observed
in the crystal structure of the free antitoxin, is intrinsically
disordered in solution. The CD spectrum of a peptide en-
compassing residues Asn3 to Asn33 is typical for a ran-
dom coil polypeptide with a minimum below 200 nm and
a very weak ellipticity above 210 nm (blue curve, Figure
2B). The CD spectrum of the N-terminal region in its na-
tive state (attached to the C-terminal domain) was esti-
mated by calculating the difference spectrum between full
length VcHigA2 and a truncate (VcHigA2N) consisting
of amino acid residues 37–104. The latter protein, which
mirrors the residues seen in the crystal structure, is thermo-
dynamically stable and shows a CD spectrum with essen-
tially the same -helical content as the full length protein
(Figure 2B). The difference spectrum is similar to the spec-
trum of the isolated peptide and suggests presence of the
random coil structure (gray and blue curves, Figure 2B).
Further evidence for an N-terminal intrinsically disor-
dered domain comes from SAXS experiments. The normal-
ized Kratky plot of VcHigA2 shows a bell-shaped curve
(typical for a globular macromolecule), followed by a con-
tinuous increase of the intensity at higher scattering angles
(a sign of flexibility) (Figure 2C, inset). Such a shape is char-
acteristic for a protein consisting of a globular domain con-
nected to an IDP domain (52). Together with the CD data,
this thus agrees with a model in which the VcHigA2 anti-
toxin has a well-structured dimeric C-terminal domain, as
seen in the crystal structure, and ∼36 amino acids long dis-
ordered N-terminal segment.
Based on these assumptions we applied the Ensemble
Optimization Method (43) to derive a model for the struc-
tural ensemble of the full-length antitoxin. The minimal en-
semble model that satisfactorily describes the data includes
seven conformations (Figure 2C and D, model statistics are
given in Supplementary Table S3). Interestingly, these con-
formations belong to two structural groups. One contains
extended conformations of the N-terminal domain, while
the other is characterized by more compact conformations.
The structural parameters for all conformations of the rep-
resentative ensemble are given in Supplementary Table S4.
The N-terminal domain of VcHigA2 inhibits VcHigB2
through folding upon binding
Increasing amounts of VcHigB2 abolish synthesis of the
reporter protein in an in vitro translation assay and half-
maximal inhibition is observed at 5 nM concentration
of VcHigB2 toxin (Supplementary Figure S4, (28)). Ad-
dition of VcHigA2 in stoichiometric amounts inactivates
VcHigB2 (Figure 3A). Interestingly, peptides derived from
theVcHigA2 N-terminus also counteract the activity of the
toxin (Figure 3A). The minimal element for toxin inhibi-
tion is the VcHigA2 peptide encompassing residues Asn3-
Glu22, which corresponds to the segment that folds into an
-helix upon toxin binding (see below). Using an in vitro ri-
bosome binding assay we also observe that theVcHigA23-22
peptide preventsVcHigB2 binding to the ribosomes (Figure
3B). Thus the intrinsically disordered N-terminal domain is
sufficient for VcHigB2 toxin regulation.
The interaction between VcHigA2 and VcHigB2 is char-
acterized by a very high affinity and by structuring of the
antitoxin N-terminal domain. Coupled folding and bind-
ing is evident from the comparison of the CD spectra from
free and the VcHigB2-bound VcHigA2 (Figure 3C). The
interaction was studied using ITC and the corresponding
thermodynamic parameters were obtained by global fitting
of the model function (Equation 1) to the titration curves
measured at four different temperatures (seeMethods). This
procedure ensures that the parametersGb◦,Hb◦, TSb◦
and c◦p,b are reliable within the error margins as deter-
mined from the Monte Carlo error propagation analysis
(Figure 3D and Supplementary Figure S6). The dissocia-
tion constant of the VcHigB2–VcHigA2 complex is 50 pM
(at 25◦C; Gb◦ = −14.1 ± 0.5 kcal mol−1). Binding is
driven by a high negative enthalpy change (Hb◦ =−26.6±
0.9 kcal mol−1) and is opposed by an unfavorable entropy
contribution (TSb◦ = −12.5 ± 1.0 kcal mol−1). Similar
thermodynamic characteristics were observed also for high-
affinity binding of the intrinsically disordered CcdA anti-
toxin domain to the toxin CcdB from ccdAB TA module
(53). The negative enthalpy change likely originates from
the folding of the N-terminal domain (in particular the for-
mation of an-helix) and from specific interactions between
VcHigB2 and VcHigA2. The unfavorable entropic contri-
butions likely originate from the reduction of rotational and
translational degrees of freedom due to the association of
VcHigB2 and VcHigA2 molecules and from the reduction
of conformational degrees of freedom due to the folding of
the N-terminal domain of VcHigA2. Moreover, the bind-
ing is associated with a decrease of the heat capacity. The
obtained experimental value of −0.95 kcal mol−1 K−1 is in
agreement with the corresponding heat capacity change es-
timated on the basis of changes of the accessible surface ar-
eas (−1.05 ± 0.08 kcal mol−1 K−1) (45) and suggests that
the binding is accompanied by a favorable desolvation en-
tropy contribution.
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Figure 2. VcHigA2 antitoxin has two domains. (A) Crystal structure of the VcHigA2 C-terminal DNA-binding domain. Two monomers are in different
colors. Helix-turn-helix motif is indicated on one monomer. (B) CD spectra of the full-lengthVcHigA2 (orange) and the N-terminal truncateVcHigA2N
(red) have very similar intensities indicating that theN-terminus is unstructured. The difference spectrum (VcHigA2-VcHigA2N) corresponding to theN-
terminal domain in the full-length antitoxin (gray) has features typical of random coil and is very similar to the that of theN-terminal peptideVcHigA23-33
(blue). Intensities for blue and gray spectra are given on the right y-axis. (C) Themeasured SAXS curve of the full-length antitoxin (orange) is superimposed
on the calculated scatter of the EOM-derived model (blue). The extended, folded conformation of the VcHigA2 as observed in the VcHigBA2 complex
is not compatible with the SAXS data (yellow). Inset: the normalized Kratky plot is in agreement with the presence of a globular domain combined with
a flexible segment. (D) The representative EOM-derived model of the full-length antitoxin consists of seven conformations of the N-terminal domain (in
different colors).
Structure of the heterotetrameric VcHigBA2 complex
Crystals of the VcHigBA2 complex contain a VcHigA2
dimer of which the extended N-termini fold and wrap
around VcHigB2 to form an elongated HigB2-HigA2-
HigA2-HigB2 heterotetramer (Figure 4A). The electron
density is clear and continuous except for the affinity tags
and again the positively charged 2-3 loop of VcHigB2.
The N-terminal region of VcHigA2 folds into an N-
terminal -helix (residues 3–22) followed by a short -
strand (residues 28–37). This -strand is added to the -
sheet core of VcHigB2 while the -helix binds along the -
sheet surface. The structure of the N-terminal segment of
VcHigA2 does not possess a hydrophobic core on its own,
in agreement with our observations that in solution and in
absence of VcHigB2, this segment remains unfolded.
The interaction betweenVcHigA2 andVcHigB2 buries a
total of 5300 A˚2 of solvent accessible surface, most of which
is accounted for by the binding of the antitoxin N-terminal
helix. Nonpolar residues along one side of the VcHigA2 N-
terminal helix are facing the -sheet surface of VcHigB2,
thereby creating an extended hydrophobic core (Figure 4B).
On the opposite side of the VcHigA2 N-terminal helix sev-
eral charged residues tighten the binding via electrostatic
interactions (Figure 4B). In addition to the interactions
with the N-terminal domain of VcHigA2, there is an ad-
ditional binding interface employing the globular domain
of VcHigA2. This involves positioning of the VcHigB2 2
helix into a hydrophobic cleft formed by helices 2 and
3 of the VcHigA2 antitoxin. However, the observed ITC
curves accompanying binding of the VcHigA23-22 peptide
and the full-length antitoxin to the VcHigB2 are very simi-
lar, suggesting that themajor contributions to binding affin-
ity come from the interaction betweenVcHigA2N-terminal
domain and VcHigB2 while the interactions between the
globular domains are less important (Supplementary Fig-
ure S7). This is in line with our activity experiments that
suggest that the first 20 amino acids from the disordered
HigA2 N-terminus regulate the toxin activity.
Conformational changes ofVcHigB2 uponVcHigA2 binding
Comparison of the conformations of VcHigB2 in the
nanobody complexes with the conformation observed in the
VcHigBA2 complex reveals two major differences: a dis-
placement of the C-terminal helix 3 and a one-residue reg-
ister shift in -strand 3 (Figure 4C). The helix displacement
is a direct consequence of the interaction with N-terminal
helix of VcHigA2, since both helices compete for an over-
lapping anchor site on the-sheet surface (Figure 4C). In its
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Figure 3. Inhibition of the VcHigB2 toxin by the VcHigA2 antitoxin. (A) Fluorescent reporter protein is synthesized in the in vitro translation assay and
addition ofVcHigB2 toxin (at 50 nM, 10 times above its IC50) inhibits its synthesis. Addition of BSA (at 1M) has no effect on toxin activity, while peptides
derived from the N-terminus of VcHigA2 antitoxin (VcHigA23-22 and VcHigA23-33) as well as full-length antitoxin inhibit toxin activity. Concentration of
VcHigB2 toxin was constant 50 nM. Fluorescence of the reporter protein (eGFP) was normalized using the values for the positive (no toxin) and negative
controls (no eGFP coding fragment). (B) Top: ribosome profiles from ultracentrifugation on a sucrose gradient. Bottom: anti-his western blot of the protein
and ribosomal fractions show that VcHigA23-22 prevents binding of the VcHigB2 toxin to the ribosome. (C) Binding to the toxin is coupled by the folding
of the antitoxin. CD spectrum of the bound antitoxin estimated as the difference spectrum between VcHigBA2 complex and VcHigB2. (D) Calorimetric
titrations of toxin into antitoxin performed at different temperatures. Global fits of the model function (Equation 1) to the data measured at different
temperatures are shown as solid lines.
novel position the 3 is rotated by∼30◦. TheN-end roughly
retains its original position, while the C-end is displaced
by ∼13 A˚ compared to its position in the nanobody-bound
VcHigB2.
-strand 3 consists of amino acid sequence 63-
SRIIYYFL-70 and its central residues are part of the
VcHigB2 hydrophobic core. The electron density of this
sequence is clear and allows unambiguous tracing of the
polypeptide chain from the Arg60 or Gly62 in the in
nanobody-VcHigB2 structures (Figure 5A). Surprisingly,
when this model is used to refine the structure of the
VcHigBA2 complex, clear difference peaks in mFo-DFc
maps suggested an alternative tracing of the polypeptide
(Figure 5B). A model with the amino acid sequence of 3
shifted by one residue (−1 shift in the -strand register)
clearly describes the data better (Figure 5C). Remarkably,
this shifted conformation does not disrupt the hydrophobic
packing interactions between-sheet and the helices1 and
2 of the VcHigB2, because the four central hydrophobic
residues are a repeat (65-IIYY-68), and therefore the posi-
tions of Ile65 and Tyr67 (in the Nb−VcHigB2 complexes)
are mimicked by Ile66 and Tyr68 in the VcHigBA2 com-
plex (Figure 5D). The shift in the -strand register comes
with a structural change likely crucial for the activity of the
VcHigB2 toxin. In the nanobody complexes Arg64, which
is part of the active site, is oriented correctly relative to the
other active site residues (in-conformation). In contrast, in
theVcHigBA2 complex the register shift flips this side chain
to the opposite plane of the -sheet (out-conformation)
(Figures 4C and 5D). In the slided conformation the 3-4
loop is one residue shorter, while 2-3 loop is extended for
one residue, but remains disordered in both conformations.
DISCUSSION
The higBA module on plasmid Rts1 was the first TA mod-
ule discovered with an inverted gene organization, the toxin
gene being located upstream of the antitoxin gene. Since
then, the name ‘higBA’ has been used for a plethora of TA
modules where a toxin gene (weakly) related to relE is fol-
lowed by an antitoxin gene that encodes a helix-turn-helix
DNA binding motif. Our crystal structures show that the
proteins encoded by the V. cholerae chromosomal higBA2
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Figure 4. Structure of the heterotetrameric VcHigBA2 complex. (A) Overall structure of the complex. The two VcHigB2 toxins are in red, the two chains
of the antitoxin dimer are in gray and blue. (B) Interactions between the toxin and the antitoxin’s N-terminal domain. The electrostatic surface of the
VcHigB2 toxin was calculated with ABPS using default parameters (60). (C) Conformational changes in the VcHigB2 induced by binding to VcHigA2.
The antitoxin N-terminal helix (blue) partially displaces the VcHigB2 C-terminal helix (toxin in its free state is shown in gold, toxin in the bound state in
red) and shifts the register of the -strand 3 (green). The two positions of the catalytically important Arg64 are shown in sticks.
module differ in significant aspects from those of the plas-
mid encoded Rts1 module (17) and that defining a distinct
higBA family based solely on the gene order of toxin and
antitoxin may be misleading. The toxin VcHigB2 shows a
much stronger similarity to the classic E. coli RelE both in
terms of overall structure and in its atypical combination
of the catalytic residues. The most striking difference be-
tween VcHigB2 and EcRelE is the sequence of loop 2-3,
which in VcHigB2 is longer, rich in lysines and remains dis-
ordered. Substitution of this loop for a sequence of three
alanines impairs toxin activity (Figure 1C). Superposition
of VcHigB2 on ribosome-bound EcRelE (PDB ID: 4V7J,
(12)) suggests that this loop might form extensive interac-
tions with the 16S RNA helices 18 and 34 (Figure 6A).
EcRelE interacts with the ribosomal RNA via two Lys and
Arg-rich patches involving helices 1 and 2 (12). The same
basic patches also mediate binding to the ribosomal A site
in YoeB, YafQ and PvHigB mRNAses (13,14,54). Surpris-
ingly inVcHigB2, helices 1 and 2 are not charged and su-
perposition ofVcHigB2 on ribosome-bound EcRelE shows
minimal contacts between the ribosomal RNA and helices
1 and 2 of VcHigB2 (only Lys13 from 1 seems to inter-
act with 16SRNAhelix 31). Given the absence of other con-
tacts between the ribosome scaffold and theVcHigB2 toxin,
the positively charged 2-3 loop likelymediates binding of
the VcHigB2 to the ribosomal A site by electrostatic inter-
actions with the 16S RNA.
The relation between V. cholerae higBA2 and E. coli
relBE comes with an interesting switch in genetic organi-
zation. Not only does the VchigBA2 module have an in-
verted gene organization, the arrangement of the two func-
tional domains of theVcHigA2 antitoxin is inverted as well.
The intrinsically disordered toxin-neutralizing domain is lo-
cated N-terminal to the DNA binding domain, unlike in
the EcRelB as well as most other modular antitoxins (55).
In stark contrast, PvHigA lacks the toxin-binding intrinsi-
cally disordered domain and binds the toxin with the glob-
ular domain (17). The IDP domain of VcHigA2 folds upon
binding in an extended structure consisting of an -helix
followed by a -strand. This motif is omnipresent in relBE-
related TAmodules (e.g. dinJ-yafQ, yoeB-yefM, (55)) where
this -helix acts as the main regulatory element to control
the activity of the toxin.
The inhibition of the ribosome-dependentmRNases such
as VcHigB, RelE, YoeB and YafQ by their cognate antitox-
ins, can be explained by the formation of large TA com-
plexes, which cannot enter the ribosomal A site. Yet, in all
cases the previously mentioned -helical toxin-binding mo-
tif are sufficient to neutralize these toxins, often involving
rearrangements in the active sites. For example, binding of
the YefM C-terminal helix to YoeB induces a conforma-
tional rearrangement of the active site residues of the YeoB
toxin (15). The C-terminal domain of DinJ directly cov-
ers the active site of the YafQ toxin (19,20) and binding of
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Figure 5. Sliding of VcHigB2 strand 3. (A) Model of the strand 3 from the Nb6-VcHigB2 structure and the corresponding 2mFo-DFc map contoured
at 1  (resolution 1.85 A˚). (B) Positive (green) and negative (red) peaks in the mFo-DFc map contoured at 3  suggest a different tracing of the sequence
of strand 3 in the VcHigBA2 complex. (C) 2mFo-DFc and mFo-DFc maps (contoured at 1  and 3 , respectively; resolution 3 A˚) for the final model of
strand 3 in the VcHigBA2 complex. (D) Schematic figure displaying strand 3 in both conformations. Unstructured 2-3 loop is shown as dashed line,
locations of the active site and solvent-inaccessible hydrophobic core are circled. Slided conformation (bottom) does not perturb the hydrophobic packing
due to a sequence repeat.
EcRelB displaces the C-terminal helix of EcRelE, thereby
distancing the catalytically important Tyr87 from the ac-
tive site (16). Thus, in general short toxin-binding motifs
act as minimal regulatory elements for the corresponding
toxins and the perturbation of the active site is a general
strategy for toxin inhibition. Indeed, our data show that
theVcHigA2N-terminal domain containing the neutraliza-
tion helix (peptide VcHigA23-22) is sufficient to neutralize
VcHigB2 (Figure 3A).
Like the C-terminal -helix of EcRelB, the N-terminal
-helix from VcHigA2 displaces helix 3 of VcHigB2. Dis-
placement of 3 of VcHigB2 does not perturb the active
site ofVcHigB2 directly and in contrast toEcRelE this helix
does bear a catalytically important residue. Indeed the func-
tional equivalent of Tyr87 located on helix 3 of EcRelE
is Tyr82 which is located on strand 4 of VcHigB2 (Fig-
ure 1B). Even though there are no obvious large clashes
between peptide-bound VcHigB2 and the ribosome scaf-
fold (Figure 6B) the VcHigA23-22 peptide prevents bind-
ing to the ribosome (Figure 3B).This may be explained by
the observation of dynamic nature of the 3 strand. In
the slided conformation the Arg64 can be found in or out
of the active site due to the shift in the -strand register
(Figure 5D). Its structural homolog Arg61 from EcRelE
binds the mRNA molecule and has been identified as sta-
bilizer of the negatively charged transition state (51). In all
three nanbody-VcHigB2 structures the Arg64 is found in
the active in-conformation and interacts with the sulphate
or phosphate ions from the crystallization solution (Figure
1A). On the other hand in the structure of the VcHigBA2
complex, Arg64 is flipped to the other side of the -strand
and is no longer part of the active site and it cannot inter-
act withmRNAmolecule.Moreover, sliding of the 3 stand
also extends the 2-3 loop, which probably disrupts inter-
actions with the ribosome (Figure 6B).
The sequence of strand 3 seems to acts as a ‘chameleon’
sequence and the VcHigB2 exists in two conformations
(active ‘in’ and non-active ‘out’). This -strand sliding to-
ward the ‘out’ conformation would then need to be induced
though the binding of the N-terminal helix of VcHigA2. In
addition, the interaction of VcHigB2 loop 2-3 with the
ribosome may help to stabilize the active ‘in’ conformation.
Several examples of functional shifts in the -strand regis-
ters have also been described in other proteins, for example
during the signal transduction of the BLUF photoreceptor
(56,57) and in the Arf1 and Arl3 GTPases (58,59), but the
mechanism of -strand sliding is poorly understood. This
is the first observation of -strand sliding in a ribonuclease
and further research might clarify how the two conforma-
tions of VcHigB2 are interconverted.
ACESSION NUMBERS
PDB IDs: 5J9I, 5JA8, 5JA9, 5JAA and 5MJE.
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Figure 6. Model of theVcHigB2 toxin bound to the ribosome. The model
was obtained by the superposition of the VcHigB2 toxin on EcRelE in
the EcRelE–ribosome complex (PDB ID: 4V7J). (A) VcHigB2 positively
charged 2-3 loop (highlighted in yellow) interacts with helies 18 and
34 from the 16S RNA. The conformation of the 2-3 loop was opti-
mized using ModLoop web server (61). (B) VcHigB2 toxin with bound
VcHigA23-33 peptide placed in the VcHigB2 binding site of ribosome us-
ing theEcRelE–ribosome complex (PDB ID: 4V7J) as a guide. No obvious
clashes are observed between the ribosome or the mRNA substrate and
VcHigB2 or VcHigA23-33.
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